• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal & Metabolism
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality
      • Environment, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Vasant (Vas) Narasimhan, M.D., Chief Executive Officer of Novartis

Vasant (Vas) Narasimhan, M.D.

Chief Executive Officer of Novartis

  • linkedin
  • twitter
  • instagram

Nationality: American
Year of Birth: 1976

Vas Narasimhan, M.D., has been Chief Executive Officer (CEO) of Novartis since 2018. Since becoming CEO, Dr. Narasimhan has led a strategic and cultural transformation at Novartis to build a leading medicines company globally powered by advanced therapy platforms and data science. Under his leadership, the company has completed over USD 70 billion in strategic transactions.

Dr. Narasimhan was the Global Head of Drug Development and Chief Medical Officer for Novartis from 2016 to 2018. Prior to that, he held a range of leadership roles in product development and general management, such as Global Head of Development for Novartis Pharmaceuticals from 2014 to 2016; Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit in 2014; Global Head of Development for Novartis Vaccines from 2012 to 2014; and North America Region Head for Novartis Vaccines, as well as United States Country President for Novartis Vaccines and Diagnostics, from 2008 to 2012. During his career at Novartis, Dr. Narasimhan has overseen the licensure of over 30 novel medicines, including cell and gene therapies and vaccines.

Dr. Narasimhan received his doctor of medicine from Harvard Medical School, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the U.S. During and after his medical studies, he worked extensively on a range of public health issues in low- and middle-income countries, and he continues to champion global health priorities today. Dr. Narasimhan is a member of the National Academy of Medicine and sits on the board of fellows of Harvard Medical School. He also serves on the boards of African Parks, a nonprofit conservation organization, and of the Pharmaceutical Research and Manufacturers of America.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

You are here

  1. Home ›
  2. Our Company ›
  3. Executive Committee

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.